Prenatal screening in the first trimester has evolved considerably over the past two decades, offering pregnant women earlier and more nuanced information about their pregnancies. Among these early screenings, nuchal translucency (NT) measurement is one that many women — particularly those pregnant after 35 — encounter as part of their prenatal care. Understanding what this screening involves and what its results mean can help reduce anxiety and support informed decision-making.
The nuchal translucency scan is an ultrasound-based measurement taken between 11 and 14 weeks of pregnancy. It measures a fluid-filled space at the back of the baby’s neck. All fetuses have some fluid in this area; the screening assesses whether the measurement falls within a range associated with typical development or outside a range that may warrant further evaluation. This is part of the broader landscape of prenatal testing options after 35.
What Research Shows About NT Screening
According to guidelines from the American College of Obstetricians and Gynecologists, nuchal translucency measurement combined with first-trimester blood markers forms the “combined first-trimester screen.” This combined approach has a detection rate for Down syndrome of approximately 82–87%, with a false-positive rate of around 5%.
It’s important to understand that first-trimester screening — including NT — is a screening test, not a diagnostic test. A screen-positive result means there is an increased statistical probability of certain chromosomal conditions; it does not confirm a diagnosis. Diagnostic certainty requires additional testing such as chorionic villus sampling (CVS) or amniocentesis.
Why NT Screening Is Particularly Relevant After 35
The statistical likelihood of certain chromosomal conditions, including trisomy 21, increases with maternal age. For this reason, prenatal screening options are routinely discussed as part of pregnancy care after 35. It’s equally important to note that the majority of pregnancies after 35 result in chromosomally typical babies. Age increases the probability of certain conditions; it does not make them inevitable.
What Happens During the Scan
The NT ultrasound is typically performed between 11 weeks and 13 weeks 6 days of pregnancy. It is usually done transabdominally or transvaginally depending on fetal position. A trained sonographer or perinatologist performs the measurement. The accuracy of the measurement depends on timing, fetal position, and sonographer training. The blood draw for associated markers (PAPP-A and free beta-hCG) is usually done around the same time.
Understanding Your NT Results
Normal NT Measurements
NT measurements are generally considered within typical ranges when below approximately 2.5–3.0 mm, though the specific threshold can vary slightly by gestational age. A measurement in the typical range, combined with reassuring blood markers, generally yields a screen-negative combined result.
Elevated NT Measurements
An elevated NT measurement does not diagnose a chromosomal condition. Increased NT has been associated with chromosomal differences as well as some structural heart conditions, and in some cases it reflects normal variation with no identified cause. When NT is elevated, additional evaluation is typically recommended — including a detailed anatomy ultrasound and potentially fetal echocardiography.
Additional Options: Cell-Free DNA Screening
Cell-free DNA (cfDNA) testing, sometimes called non-invasive prenatal testing (NIPT), analyzes fetal DNA fragments present in maternal blood and has higher detection rates for trisomies 21, 18, and 13 than the combined first-trimester screen. NIPT is also a screening test, not diagnostic — positive results should be confirmed with CVS or amniocentesis before any major decisions are made. Understanding what to expect in the first trimester after 35 can help you prepare for these conversations.
Frequently Asked Questions
Is NT screening required during pregnancy after 35?
No prenatal screening test is required. NT screening and first-trimester combined screening are offered and recommended for discussion, but the decision to pursue them is personal. Your OB/GYN or midwife can explain the options available and help you consider what information would be most useful for your decision-making.
What happens if my NT result is abnormal?
An elevated NT measurement leads to further evaluation rather than an immediate diagnosis. Your provider will typically recommend follow-up ultrasound and will discuss diagnostic testing options. The vast majority of patients with elevated NT results who pursue diagnostic testing receive reassuring results, though individual outcomes vary.
How accurate is NT screening?
As part of the combined first-trimester screen, NT has a detection rate of approximately 82–87% for trisomy 21 with a false-positive rate of about 5%. cfDNA testing has higher detection rates, though it too has limitations.
Does a normal NT result guarantee a healthy baby?
No screening test can guarantee any particular outcome. A normal NT combined with reassuring blood markers substantially reduces the statistical likelihood of certain chromosomal conditions, but does not eliminate all risks. Normal screenings are reassuring, but pregnancy involves inherent uncertainty that no test can fully eliminate.
Key Takeaways
- Nuchal translucency screening, performed between 11 and 14 weeks, is part of first-trimester combined screening for chromosomal differences.
- NT screening is a screening test, not a diagnostic test — results indicate probability, not certainty, and screen-positive results require further evaluation.
- Women over 35 are at statistically higher risk for certain chromosomal conditions, though the majority of pregnancies after 35 result in chromosomally typical babies.
- cfDNA (NIPT) testing offers an alternative or complement to combined first-trimester screening with higher detection rates.
- Decisions about prenatal screening are personal and should be made in discussion with your OB/GYN.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.